Trials and therapies in secondary progressive MS, simplified

Nature Reviews Neurology, Published online: 08 July 2019; doi:10.1038/s41582-019-0233-xThe FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research